Area of research
Hepatology · Oncology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Cholangiocarcinoma and Gallbladder Cancer Studies, and Pancreatic and Hepatic Oncology Research.
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study.
Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study.
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis.
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient.
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
Lenvatinib as Second-Line Regimen after Atezolizumab plus Bevacizumab Combination Therapy.
Pattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials.
A Rare but Life-Threatening Complication of Direct Endoscopic Necrosectomy: Tension Pneumoperitoneum With Pneumothorax and Hypercapnia due to Walled-Off Necrosis Rupture.
A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma.
Response to the letter to the editor regarding "Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients".
Impact of Early-Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti-VEGF Agents.
Diagnostic Utility of Endoscopic Features and Endoscopic Ultrasonography for Ulcerative Colitis-Associated Neoplasia: A Retrospective Study on the Role of Endoscopic Submucosal Dissection as a Total Biopsy.
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.
Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRI.
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study.
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.
Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab.
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early-Stage Viral Disease.
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
A Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial
Efficacy of nivolumab plus ipilimumab in advanced hepatocellular carcinoma with and without high-risk features: an international multicenter study
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma
Characterization of Patients with Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated with Lenvatinib
The China Paradox in LEAP-012 tiral
Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC